Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Neurologic Other
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Neurologic Other
    Small Bedside Monitors Detect Seizures in At-Risk Newborns - (DGNews)
    Early Gastric Feeding Following Traumatic Brain Injury Improves Likelihood for Survival - (DGNews)
    Silent Cerebral Infarction Reported in 10% of Healthy People - (DGNews)
    Subtle Nervous System Abnormalities Predict Risk of Death in Elderly - (DGNews)
    Incident Dementia Reduced by Antihypertensive Therapy in Elderly Hypertensive Patients: Presented at ESH - (DGDispatch)

    News archive

     Recent webcasts/CME - Neurologic Other
    • Dementia in Hispanic Americans: The Reasons Behind the Risk
    • Modifiable Risk Factors Underlie Higher Dementia Rates in African Americans
    • Battling Chronic Fatigue Syndrome
      Brain Cooling for the Treatment of Perinatal Hypoxic-Ischemic Encephalopathy
      Delirium Update

      Webcasts/CME archive

       Recent cases - Neurologic Other
        Solitary Skull Metastasis as Initial Manifestation of Hepatocellular Carcinoma
        Perthes Syndrome Associated with Intramedullary Spinal Cord Hemorrhage in a 4-Year-Old Child: A Case Report
        Snake Bite Mimicking Brain Death
        Henoch-Schonlein Purpura with Intracerebral Haemorrhage in an Adult Patient: A Case Report
        Compression of the Median Nerve in the Proximal Forearm by a Giant Lipoma: A Case Report

        Cases archive
          




        my personal edition > neurologic other > news
        divider

          E-Mail this DGDispatch to a colleague

        DGDispatch


        Pregabalin Cuts Pain in Tough-to-Treat Patients With Neuropathic Pain and Fibromyalgia Syndrome: Presented at AAN

        By Jill Stein

        MIAMI, FL -- April 13, 2005 -- Use of pregabalin and concomitant analgesics if required is able to maintain stable pain reduction in patients with diabetic peripheral neuropathy (DPN), postherpetic neuralgia (PHN), or fibromyalgia syndrome (FMS) that is refractory to therapy with tricyclics, gabapentin, and other analgesics.

        Pregabalin was recently approved in the United States for the treatment of neuropathic pain associated with painful DPN and PHN.

        The new findings were reported by Joao Siffert, MD, medical director for worldwide neurology, Pfizer Global Pharmaceuticals, New York, New York, United States, here on April 12th at the American Academy of Neurology 57th Annual Meeting.

        Dr. Siffert presented findings from the first 15 months of an ongoing open-label trial that is examining the effectiveness and safety of pregabalin in treatment-refractory patients with DPN and PHN as well as pain associated with FMS.

        The 106 patients in whom data were reported had participated in double-blind, placebo-controlled pregabalin trials and had documented inadequate pain relief or intolerable adverse effects during at least 2 weeks of treatment with a tricyclic antidepressant (75 mg/day or more), gabapentin (1800 mg/day or more), and at least 1 third-line neuropathic pain treatment.

        During the trial, patients were allowed to continue concomitant medications, including gabapentin, and were allowed to initiate use of other pain medications.

        Subjects received pregabalin 150 to 600 mg/day adjusted to effectiveness and tolerability.

        The study included 4 quarterly drug holidays followed by relapse visits where patients indicated if their pain worsened on a 5-point scale where 0 meant "not at all" and 4 meant that their pain was "very much worse".

        Relapse was defined as a response of "moderately worse" (3 points) or greater. Only patients who relapsed during a drug holiday resumed pregabalin treatment.

        Visual Analogue Scale (VAS) mean pain scores at baseline were 73 for DPN patients, 74 for PHN patients, and 75 for FMS patients. Pregabalin treatment yielded significant reductions in pain scores at the end of the study, with mean VAS pain scores of 47 for DPN, 55 for PHN, and 48 for FMS.

        The mean duration of drug holidays was 7 days.

        Pregabalin drug holidays were consistently associated with a return of pain VAS scores to baseline levels, further establishing the association of pregabalin use and pain reduction, Dr. Siffert noted.

        Adverse events associated with treatment were typical of those observed with pregabalin in prior clinical trials and indicated generally good tolerability.

        The study was sponsored by Pfizer Inc.


        [Presentation title: Long-Term Treatment of Neuropathic Pain and Fibromyalgia Syndrome With Pregabalin in Treatment-Refractory Patients. Abstract P02.156]



        E-Mail this DGDispatch to a colleague   To print, use this version






        All contents Copyright (c) 1995-2008 Doctor's Guide Publishing Limited. All rights reserved.



        The NTK initiative. Physicians helping physicians identify Need-To-Know science
           Feedback
        Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
        Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
        1
        2
        3
        4
        5
        6
        7
        Send